Bortezomib 2mg
Bortezomib is a targeted therapy. It is classified as a proteasome inhibitor.
Used for
- Treatment of multiple myeloma.
- Treatment of mantle cell lymphoma who have received at least one prior therapy.
Given as
- As an intravenous (into the vein) injection.
- As a subcutaneous (under the skin) injection into the thigh or abdomen.